Rising Bacterial Infections And The Surge In Demand For Carbapenem-Based Antibiotics Is A Driving Force In Market Expansion Emerges as a Core Driver of the Carbapenem-Based Antibiotics Market in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Carbapenem-Based Antibiotics Market Through 2025?
There has been a consistent growth in the size of the carbapenem-based antibiotics market in the past few years. The market size is predicted to increase from $4.6 billion in 2024 to $4.78 billion in 2025, reflecting a compound annual growth rate (CAGR) of 3.8%. The historical growth has been driven by factors such as epidemics and pandemics, surge in chronic diseases, development in healare infrastructure, fast-paced urbanization, natural catastrophes, and health crises.

What's the Projected Size of the Global Carbapenem-Based Antibiotics Market by 2029?
In the coming years, a significant surge is expected in the size of the carbapenem-based antibiotics market. It is predicted to increase to " $5.97 billion by 2029 with a compound annual growth rate (CAGR) of 5.7%. The anticipated growth in the forecast period could be due to a rise in hospital-acquired infections, the appearance of multi-drug resistant strains, an expanding elderly population, an increase in surgical procedures, spreading infectious diseases, and shifting demographics. Key trends for the forecast period involve supply chain resilience and security, the development of alternative treatments, a shift towards outpatient settings, rising knowledge about antimicrobial stewardship, and the use of precision medicine approaches.

View the full report here:
https://www.thebusinessresearchcompany.com/report/carbapenem-based-antibiotics-global-market-report

Top Growth Drivers in the Carbapenem-Based Antibiotics Industry: What's Accelerating the Market?
The escalating prevalence of bacterial infections is anticipated to fuel the expansion of the market for carbapenem-based antibiotics. Such infections are triggered by bacteria, microscopic entities that may infiltrate the human body and trigger various diseases and symptoms. These antibiotics are effective treatments for serious or multi-drug-resistant bacterial infections, covering those stemming from gram-positive and gram-negative bacteria. For example, the Centers for Disease Control and Prevention, a government agency in the US, reported in July 2024 that in 2023, 78% of all bacterial infections were diagnosed by CIDTs in the historical catchment area, of which 46% were diagnosed solely using CIDTs. Consequently, the rising prevalence of bacterial infections stimulates the expansion of the market for carbapenem-based antibiotics.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12035&type=smp

Which Emerging Trends Are Transforming the Carbapenem-Based Antibiotics Market in 2025?
The primary trend taking root in the carbapenem-based antibiotics market is the creation of innovative products by leading companies to maintain their market footing. The National Health Service, a government agency in the UK, partnered with the pharmaceutical industry to roll out an innovative antibiotic subscription scheme in August 2024 to battle antimicrobial resistance (AMR). Unveiled on August 12, 2024, this revolutionary system allows pharmaceutical manufacturers to acquire fixed yearly fees-up to £20 million per drug-uncoupled from the amount prescribed, thereby negating encouragement for excess use. Valued at roughly £1.9 billion across 16 years, the initiative seeks to spur the creation of new antibiotics by assuring financial sustainability for pharma firms. Following a successful trial phase, this initiative is now a part of the wider UK strategies to combat AMR, an issue that could potentially escalate into a major global health concern, possibly causing millions of deaths by 2050 if not countered. The NHS will give preference to products that aim at critical pathogens as identified by the World Health Organization, thus underlining its dedication to responsible antibiotic use and the advancement of antibiotic innovation.

What Are the Main Segments in the Carbapenem-Based Antibiotics Market?
The carbapenem-based antibiotics market covered in this report is segmented -

1) By Type: Meropenem, Imipenem, Doripenem, Tebipenem, Other Types
2) By Indication: Intra-abdominal Infections, Urinary Tract Infections, Pneumonia, Bacterial Meningitis, Skin And Skin Structure Infections, Acute Pelvic Infections, Prophylaxis of Surgical Site Infection, Respiratory Tract Infections, Gynecological Infections, Other Indications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Meropenem: Meropenem Injection, Meropenem and Vaborbactam Combination, Meropenem for Pediatric Use
2) By Imipenem: Imipenem and Cilastatin Combination, Imipenem and Relebactam Combination, Imipenem Monotherapy
3) By Doripenem: Doripenem Injection, Doripenem for Complicated Infections
4) By Tebipenem: Tebipenem for Oral Administration, Tebipenem Pediatric Formulations, Tebipenem for Resistant Infections
5) By Other Types: Ertapenem, Panipenem, Faropenem, Combinations with Beta-Lactamase Inhibitors

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12035&type=smp

Which Top Companies are Driving Growth in the Carbapenem-Based Antibiotics Market?
Major companies operating in the carbapenem-based antibiotics market include Pfizer Inc., Merck & Co. Inc., Fresenius Kabi LLC, GlaxoSmithKline Plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Meiji Holdings Co. Ltd., Sandoz International GmbH, Sumitomo Dainippon Pharma Co. Ltd., Shionogi & Co Ltd., Aurobindo Pharma Ltd., Acurx Pharmaceuticals LLC, Daewoong Pharmaceutical Co. Ltd., CeramTec GmbH, ACS Dobfar S.p.A, JW Pharmaceutical Corp, Centrient Pharmaceuticals Co, Spero Therapeutics Inc., Kopran Limited, Savior Lifetec Corporation, Flagship Biotech International Pvt. Ltd., Iterum Therapeutics plc, Cam Carbapenem-based antibiotics BV, Intelicure Lifesciences, Ikeda Corporation

Which Regions Will Dominate the Carbapenem-Based Antibiotics Market Through 2029?
North America was the largest region in the Carbapenem-Based Antibiotics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carbapenem-based antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12035

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert:
Saumya Sahay
Europe - +44 7882 955267,
Asia: +91 88972 63534,
Americas - +1 310-496-7795 or
Email:saumyas@tbrc.info
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.